Healthcare / Medical DevicesHKSE
$9.73
+0.12 (+1.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $137.1M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
12.2x
↓EV/EBITDA
8.0x
↓ROE
11.8%
↑Gross Margin
84.7%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.7%
FCF CAGR
—
FCF margin
27.4%
FCF / Net income
0.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $527.9M · net income $239.7M · FCF $144.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $527.9M | $527.9M | $471.6M | $326.6M | $247.7M |
| Net Income | $239.7M | $239.7M | $245.6M | $151.4M | $-19.8M |
| EBITDA | $278.9M | $278.9M | $288.1M | $174.9M | $18.8M |
| EPS | — | — | 0.71 | 0.44 | -0.06 |
| Gross Margin | 84.7% | 84.7% | 89.9% | 88.5% | 88.7% |
| Operating Margin | 49.1% | 49.1% | 55.7% | 45.0% | 31.6% |
| Net Margin | 45.4% | 45.4% | 52.1% | 46.3% | -8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 23.54 | 23.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $144.7M | $144.7M | $137.1M | $66.7M | $-17.8M |
| Returns | |||||
| ROE | 11.8% | 11.8% | 12.3% | 7.9% | -1.1% |
| Valuation | |||||
| P/E | 12.16 | 12.16 | 23.66 | 60.45 | — |
| EV/EBITDA | 7.95 | 7.95 | 16.32 | 45.49 | 434.12 |
| P/B | 1.66 | 1.66 | 2.92 | 4.79 | 5.22 |
| Growth & Yield | |||||
| Revenue Growth | 11.9% | 11.9% | 44.4% | 31.9% | — |
| EPS Growth | — | — | 61.4% | 833.3% | — |
| Dividend Yield | 5.9% | 5.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.71 → n/d
Residual
-53.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.